Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current Deferred Tax LiabilityNotes PayablesOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

KORU Medical Systems (KRMD) Total Current Liabilities (2020 - 2025)

KORU Medical Systems (KRMD) has disclosed Total Current Liabilities for 10 consecutive years, with $7.8 million as the latest value for Q3 2025.

  • On a quarterly basis, Total Current Liabilities rose 23.87% to $7.8 million in Q3 2025 year-over-year; TTM through Sep 2025 was $7.8 million, a 23.87% increase, with the full-year FY2024 number at $7.2 million, up 61.68% from a year prior.
  • Total Current Liabilities was $7.8 million for Q3 2025 at KORU Medical Systems, up from $6.1 million in the prior quarter.
  • In the past five years, Total Current Liabilities ranged from a high of $7.8 million in Q3 2025 to a low of $3.3 million in Q2 2021.
  • A 5-year average of $5.4 million and a median of $4.9 million in 2024 define the central range for Total Current Liabilities.
  • Peak YoY movement for Total Current Liabilities: skyrocketed 73.06% in 2022, then plummeted 35.99% in 2023.
  • KORU Medical Systems' Total Current Liabilities stood at $4.8 million in 2021, then soared by 45.22% to $7.0 million in 2022, then tumbled by 35.99% to $4.5 million in 2023, then surged by 61.68% to $7.2 million in 2024, then grew by 8.78% to $7.8 million in 2025.
  • Per Business Quant, the three most recent readings for KRMD's Total Current Liabilities are $7.8 million (Q3 2025), $6.1 million (Q2 2025), and $7.8 million (Q1 2025).